4.92
price down icon4.47%   -0.23
pre-market  Vorhandelsmarkt:  5.04   0.12   +2.44%
loading
Schlusskurs vom Vortag:
$5.15
Offen:
$5.23
24-Stunden-Volumen:
7.31M
Relative Volume:
1.25
Marktkapitalisierung:
$1.47B
Einnahmen:
$38.03M
Nettoeinkommen (Verlust:
$-146.40M
KGV:
-9.4615
EPS:
-0.52
Netto-Cashflow:
$-121.38M
1W Leistung:
+24.87%
1M Leistung:
+44.28%
6M Leistung:
+39.38%
1J Leistung:
+63.46%
1-Tages-Spanne:
Value
$4.8911
$5.23
1-Wochen-Bereich:
Value
$3.87
$5.82
52-Wochen-Spanne:
Value
$1.8906
$5.82

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name
Firmenname
Abcellera Biologics Inc
Name
Telefon
(604) 559-9005
Name
Adresse
150 W 4TH AVENUE, VANCOUVER
Name
Mitarbeiter
596
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-18
Name
Neueste SEC-Einreichungen
Name
ABCL's Discussions on Twitter

Vergleichen Sie ABCL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ABCL
Abcellera Biologics Inc
4.92 1.18B 38.03M -146.40M -121.38M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-07 Fortgesetzt Leerink Partners Outperform
2024-08-20 Herabstufung The Benchmark Company Buy → Hold
2024-02-22 Hochstufung The Benchmark Company Hold → Buy
2023-12-05 Eingeleitet KeyBanc Capital Markets Overweight
2023-11-06 Herabstufung The Benchmark Company Buy → Hold
2023-10-13 Fortgesetzt Piper Sandler Overweight
2023-02-28 Eingeleitet Cowen Outperform
2022-12-15 Eingeleitet Goldman Buy
2022-11-16 Eingeleitet Truist Buy
2021-12-21 Eingeleitet The Benchmark Company Buy
2021-11-19 Eingeleitet Piper Sandler Overweight
2021-01-05 Eingeleitet BMO Capital Markets Outperform
2021-01-05 Eingeleitet Berenberg Buy
2021-01-05 Eingeleitet Credit Suisse Outperform
2021-01-05 Eingeleitet SVB Leerink Outperform
2021-01-05 Eingeleitet Stifel Buy
Alle ansehen

Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten

pulisher
03:02 AM

What drives AbCellera Biologics Inc. stock priceExtraordinary performance - Autocar Professional

03:02 AM
pulisher
Jul 22, 2025

What analysts say about AbCellera Biologics Inc. stockBreakthrough financial growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

AbCellera Biologics Inc. Stock Analysis and ForecastDynamic portfolio growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot - Insider Monkey

Jul 22, 2025
pulisher
Jul 22, 2025

Is AbCellera Biologics Inc. a good long term investmentExplosive capital gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 21, 2025

ABCL Stock Surge: Opportunity or Caution? - StocksToTrade

Jul 21, 2025
pulisher
Jul 21, 2025

AbCellera Biologics Stock (ABCL) Opinions on Recent Price Surge - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday - Benzinga

Jul 21, 2025
pulisher
Jul 21, 2025

AbCellera Biologics (ABCL) Surges 18.75% Intraday: What’s Fueling This Biotech Breakout? - AInvest

Jul 21, 2025
pulisher
Jul 18, 2025

AbCellera Bets Big On AI Antibody Discovery And Partnerships - Finimize

Jul 18, 2025
pulisher
Jul 18, 2025

Abcellera Biologics stock hits 52-week high at $4.46 - Investing.com Australia

Jul 18, 2025
pulisher
Jul 14, 2025

AbCellera Biologics' Mysterious 8.7% Spike: What's Driving the Rally? - AInvest

Jul 14, 2025
pulisher
Jul 09, 2025

Leerink Partners Initiates Coverage on AbCellera Biologics with "Outperform" Rating and $5.00 Price Target - AInvest

Jul 09, 2025
pulisher
Jul 07, 2025

Abcellera Biologics stock hits 52-week high at 4.09 USD By Investing.com - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

AbCellera's Strategic Pivot to Internal Pipelines Fuels Growth Potential in Antibody Therapies - AInvest

Jul 07, 2025
pulisher
Jul 07, 2025

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire

Jul 07, 2025
pulisher
Jul 07, 2025

Leerink Partners Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $5 - 富途牛牛

Jul 07, 2025
pulisher
Jul 07, 2025

Abcellera Biologics stock hits 52-week high at 4.09 USD - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

AbCellera Biologics' 6% Surge: A Technical & Order-Flow Deep Dive - AInvest

Jul 07, 2025
pulisher
Jul 07, 2025

Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Leerink Partners assumes coverage on AbCellera stock with Outperform rating - Investing.com

Jul 07, 2025
pulisher
Jul 02, 2025

AbCellera Biologics' Mysterious 5.7% Spike: A Technical Deep Dive - AInvest

Jul 02, 2025
pulisher
Jun 30, 2025

AbCellera Biologics: Fueling Growth Through Strategic Partnerships and R&D Reinvention - AInvest

Jun 30, 2025
pulisher
Jun 25, 2025

AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology - Insider Monkey

Jun 25, 2025
pulisher
Jun 25, 2025

AbCellera Biologics Soars 11.41% on Partnerships, Innovation - AInvest

Jun 25, 2025
pulisher
Jun 18, 2025

AbCellera Biologics' 10.9% Surge Explained: Technical Momentum or Hidden Drivers? - AInvest

Jun 18, 2025
pulisher
Jun 13, 2025

AbCellera shareholders approve board election and auditor - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera shareholders approve board election and auditor By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera Biologics Holds Annual Shareholder Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn (ABCL) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 12, 2025

ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | ABCL Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 10, 2025

AbCellera Biologics’ Canadian Clinical Trials Approval Sparks Surge - timothysykes.com

Jun 10, 2025
pulisher
Jun 09, 2025

AbCellera Biologics Inc. (ABCL): A Bull Case Theory - MSN

Jun 09, 2025

Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):